EUVIMEDEUVIMED entdecken
Crossref

Comparison of [18F]-OC PET/CT and contrast-enhanced CT/MRI in the detection and evaluation of neuroendocrine neoplasms

Donghe Chen, Shuye Yang, Jingjing Chen, Tiancheng Li, Yinuo Liu, Xin Zhao, Tingting Zhang, Mimi Xu, Huatao Wang, Kui Zhao, Xinhui Su

European Journal of Nuclear Medicine and Molecular Imaging · 2023

DOI: 10.1007/s00259-023-06200-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Donghe Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People's R…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Neuroendocrine Tumors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Gallium-68 (68Ga)-labeled somatostatin analog (SSA) PET imaging has been widely used in clinical practice of neuroendocrine neoplasms (NENs). Compared with 68Ga, 18F has a great practical and economic advantage. Although a few studies have shown the characteristics of [18F] AlF-NOTA-octreotide ([18F]-OC) in healthy volunteers and small NEN patient groups, its clinical value needs further investigation. Herein, this retrospective study aimed to evaluate the diagnostic accuracy of [18F]-OC PET/CT in detecting NENs, as well as to compare it with contrast-enhanced CT/MRI. METHODS: We retrospectively reviewed the data of 93 patients who had undergone [18F]-OC PET/CT and CT or MRI scans. Of these patients, there were 45 patients with suspected NENs for diagnostic evaluation, and 48 patients with pathologically confirmed NENs for detecting metastasis or recurrence. [18F]-OC PET/CT images were evaluated visually and semi-quantitatively by measuring maximum standardized uptake value of tumor (SUVmax), tumor-to-background SUVmax ratio (TBR), and SUVmax of hypophysis (SUVhypophysis). A total of 276 suspected NEN lesions were found in these 93 patients. The results of histopathology or radiographic follow-up served as the reference standard for the final diagnosis. RESULTS: Forty-five patients with suspected NENs were confirmed by histopathological examination via resection or biopsy. [18F]-OC PET/CT showed high radiotracer uptake in the lesions of G1-G3 NENs. [18F]-OC PET/CT showed superior performance with 96.3% of sensitivity, 77.8% of specificity, and 88.9% of accuracy in diagnosing NENs compared to CT/MRI. When cutoffs of SUVmax, TBR, and SUVhypophysis were 8.3, 3.1, and 15.4, [18F]-OC PET/CT had the best equilibrium between sensitivity and specificity for differentiating NEN from non-NEN lesions. For a total of 276 suspected NEN lesions, the sensitivity, specificity, and accuracy of [18F]-OC PET/CT for diagnosis of NENs were 90.5%, 82.1%, and 88.8%, respectively, and were higher than those of CT and MRI. G1 and G2 NENs had higher TBR and lower CT enhancement intensity than G3. The SUVmax and TBR had a positive correlation with CT enhancement intensity in G2 rather than in G1 or G3. CONCLUSIONS: [18F]-OC PET/CT is a promising imaging modality for initial diagnosis and detecting metastasis or postoperative recurrence in NENs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyNeuroendocrine TumorsHumansGallium RadioisotopesRetrospective StudiesMagnetic Resonance Imaging

Stichwörter der Autor:innen

Contrast-enhanced CTContrast-enhanced MRINeuroendocrine neoplasmsPET/CT[18F]AlF-NOTA-octreotide

Substanzen

Gallium Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People's Republic of China.
  • Pharmacy Intravenous Admixture Services (PIVAS), The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China.
  • Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People's Republic of China. zhaokui0905@zju.edu.cn.
  • Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People's Republic of China. suxinhui@zju.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China

Zitieren

APA

Chen, D., Yang, S., Chen, J., Li, T., Liu, Y., Zhao, X., Zhang, T., Xu, M., Wang, H., Zhao, K., & Su, X. (2023). Comparison of [18F]-OC PET/CT and contrast-enhanced CT/MRI in the detection and evaluation of neuroendocrine neoplasms. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06200-9

Vancouver

Chen D, Yang S, Chen J, Li T, Liu Y, Zhao X, et al. Comparison of [18F]-OC PET/CT and contrast-enhanced CT/MRI in the detection and evaluation of neuroendocrine neoplasms. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06200-9

BibTeX
@article{Chen2023,
  author = {Chen, Donghe and Yang, Shuye and Chen, Jingjing and Li, Tiancheng and Liu, Yinuo and Zhao, Xin and Zhang, Tingting and Xu, Mimi and Wang, Huatao and Zhao, Kui and Su, Xinhui},
  title = {Comparison of [18F]-OC PET/CT and contrast-enhanced CT/MRI in the detection and evaluation of neuroendocrine neoplasms},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  doi = {10.1007/s00259-023-06200-9}
}
Kostenlos starten →